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Available online 23 July 2011Open surgery for acute, complicated type B dissection is
associated with an operative mortality in excess of 20% and
considerable morbidity including spinal cord ischaemia.1
Furthermore a mortality of 17% has recently been repor-
ted after percutaneous flap fenestration for acute type B
associated malperfusion.2 There has therefore been
considerable contemporary interest in the role of TEVAR in
both acute uncomplicated and complicated type B
dissection.
The precise definition of acute complicated type B
dissection has been recently clarified and has been defined
as symptom onset of 14 days or less, with rupture, defined
as haemorrhage outside the aortic wall or malperfusion,
defined as visceral, renal, lower extremity or spinal cord
hypoperfusion.3
The mortality and morbidity results reported in this
manuscript are excellent in comparison to historic open
repair results and contemporary TEVAR results. The authors
report a 30-day mortality rate of 4.4% and an overall
survival of 95.6% at 1 and 3 years respectively. These are
considerably better than the recently reported multicenter
US data, with a 30-day mortality of 10.8% and 1-year
survival of 70.6%.3 The 3-yr survival figures are alsoDOI of original article: 10.1016/j.ejvs.2011.05.013.
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doi:10.1016/j.ejvs.2011.06.052considerably better than the 78% reported for patients
medically treated and discharged from hospital alive after
uncomplicated type B dissection in the IRAD database4 and
also the two-year 89% survival for stable type B dissection
treated with TEVAR in the INSTEAD study.5
There are a number of possible explanations for the
better outcomes reported in current manuscript. Firstly the
mean age of the patients in this study, 42 years, is much
lower than the 59 years reported in the US data.3 This may
suggest genetic and environmental differences in the
pathophysiology of acute, complicated type B dissection in
different geographical locations. These differences should
be considered when extrapolating results from one pop-
ulation to another.
Secondly the authors collected their data retrospec-
tively and this may account for some discrepancies when
compared to data collected systematically from five
physician-sponsored investigation device exemption clin-
ical trials.3
However the most important factor that may explain the
differences in outcome of these two studies may relate to
the definition of rupture. Shu et al. define indications for
treatment as rupture in 13% and haemothorax with
impending rupture (later defined as enlarged aortic diam-
eter in the dissected region with evidence of haemothorax
and no active contrast extravasation on CT) in 60%. The US
patients mainly presented with malperfusion 72% and only
32% with rupture more tightly defined as haemorrhaged by Elsevier Ltd. All rights reserved.
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dissection frequently present with a left pleural or medi-
astinal effusion and it may be difficult to differentiate
haematoma from a reactive effusion on CT. Those patients
reported as “impending rupture” in this study may have
been considered uncomplicated by other authors.
There is no doubt that TEVAR as been an advance in the
management of acute complicated type B dissection, which
is reflected by the results reported in this study. The role of
TEVAR in the management of the larger group of patients
presenting with uncomplicated type B dissection requires
further delineation. The authors treated 130 (84%) of
uncomplicated type B dissections with TEVAR during this
study period despite evidence from INSTEAD5 that TEVAR
offers no advantage over medical management at up to two
years in this group. However we know that a proportion of
patients presenting with acute uncomplicated type B
dissection will go on to develop long-term complications,
aortic dilatation, aneurysm formation and rupture. Ideally
identifying this sub-group would allow selective early
TEVAR to prevent these complications. Recent data has
suggested that a false lumen diameter of greater than
22 mm in the upper descending aorta in the acute phase
predicted aneurysm development with 100% sensitivity
and this may be a group to target for future early
intervention.6
The endovascular techniques for dealing with acute
complicated type B dissection and in particular malperfu-
sion require further delineation. Clearly the main aim of
treatment is to cover the entry tear and expand the true
lumen in order to optimize visceral artery and lower
extremity perfusion. In this study the authors did not
perform any additional endovascular procedures to the
abdominal aorta, visceral or iliac vessels. They reflect that
one death from mesenteric ischaemia may have been
avoidable with mesenteric artery stenting. It does appear
that a proportion of patients will require additional endo-
vascular procedures including bare metal stenting of the
abdominal aorta to expand the true lumen, and mesen-
teric, renal or iliofemoral stents to maintain branch vessel
perfusion.7 Furthermore additional surgical extra-anatomic
bypass procedures may be required to maintain left
subclavian, left carotid or lower extremity perfusion.3
A suggested algorithm for best current practice in acute
complicated type B dissection would include TEVAR to
cover the entry tear, rupture point and improve the true
lumen perfusion with the distal extent of aortic cover to
the level of the diaphram or just above the coeliac axis.
Further adjunctive bare metal stenting of the infra-renal
aorta to expand the true lumen or mesenteric, renal and
iliac vessel stenting should be considered if completion
angiography demonstrates persistent malperfusion. In
addition surgical extra-anatomic bypass to maintain left
subclavian perfusion and thus reduce the risk ofneurological complications8 and also to maintain lower limb
blood flow may be necessary in some cases.3
In conclusion TEVAR alone or with adjunctive endovas-
cular techniques is rapidly becoming the treatment of
choice for acute complicated type B aortic dissection with
results reported in this and other contemporary studies
considerably better in the short-term than for open surgery
or percutaneous fenestration. The precise subset of
patients with acute uncomplicated type B aortic dissection
who will benefit from TEVAR remains less clear. The
optimum endovascular techniques in type B dissection
require further delineation and stent-graft designs specifi-
cally for dissection require further development, however
as vascular specialists we are fortunate to have consider-
ably more ammunition to deal with these complex aortic
problems than in the past.References
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